ArticleClinical and translational radiation oncology2026
Outcomes of patients with oral cavity squamous cell carcinomas with perineural invasion treated with adjuvant intensity modulated radiation therapy (IMRT).
Article in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Background: Oral cavity cancers are among the most common malignancies worldwide with increasing incidence and mortality. In patients with high-risk prognostic features, adjuvant radiation with concurrent chemotherapy improves survival. The local recurrence and survival benefit from adjuvant radiation therapy is poorly understood in patients with intermediate risk factors including perineural invasion (PNI). Methods: We performed a single institution retrospective review of 494 patients with oral cavity squamous cell carcinoma (OCSCC) treated with adjuvant intensity modulated radiation therapy (IMRT). Eligible patients included those with OCSCC who underwent surgical resection between July 2002 and August 2021 treated with adjuvant IMRT with or without chemotherapy. Survival outcomes were measured by Kaplan-Meier methodology. Results: The presence of PNI or extranodal extension (ENE) correlated with significantly worse 3-year locoregional recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), relapse-free survival (RFS), and overall survival OS in patients with OCSCC treated with surgical resection and adjuvant IMRT. Lower T category or N category as well as treatment package time less than 6 weeks correlated with significantly improved LRFS, DMFS, RFS, and OS. Conclusions: PNI is an intermediate risk factor found to be a significant negative independent prognostic indicator in our patient cohort, which can help guide clinical decision-making for patients with OCSSC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.